Advertiser / Brand · vs · Advertiser / Brand · Retailer & Marketplace
Lilly vs Walgreens
Structured technology and market comparison · 2026
Direct Feature Comparison
Lilly · vs · WalgreensPublic pharmaceutical company developing, manufacturing and marketing human medicines.
US pharmacy retailer delivering prescriptions, healthcare services, consumer goods and retail media.
Analyze all overlapping signals and tech stacks for Lilly and Walgreens
Compare mutual enterprise clients, monetization models, live market signals, and partner networks directly in the interactive Knowledge Graph.
Comparison Analysis
What is the main difference between Lilly and Walgreens?
When comparing Lilly and Walgreens, both platforms operate within the Advertiser / Brand ecosystem. Lilly is positioned as Public pharmaceutical company developing, manufacturing and marketing human medicines, whereas Walgreens focuses on US pharmacy retailer delivering prescriptions, healthcare services, consumer goods and retail media. Decision-makers evaluate both solutions when orchestrating their commercial monetization and technology stack.
What are the top alternatives to Lilly and Walgreens?
When evaluating Lilly and Walgreens, enterprise buyers also consider other platforms in Advertiser / Brand. You can discover the full competitive landscape and evaluate other alternatives by viewing their respective footprint profiles on Polaris7.
How do the corporate scale, structure, and headquarters of Lilly and Walgreens compare?
Lilly is headquartered in United States (founded in 1876) with >5,000 employees. Walgreens is based in United States (founded in 1901) with >5,000 employees. Complete ownership, subsidiary trees, and corporate affiliations are documented across Polaris7.
Market Signals
Recent Market Signals & Activity: Lilly vs Walgreens
Documented market movements, strategic partnerships, product releases, and regulatory developments mapped across Polaris7.
Lilly
Recent Signals
- ·SEC APIfinancials
10-Q Financial Filing Analysis for Lilly (2026-10-29)
Eli Lilly and Company reported strong financial results for the third quarter of 2026, driven by rapid uptake of its incretin portfolio. Total revenue reached $24.40 billion, up 39% year-over-year from $17.60 billion in Q3 2025, underpinned by massive volume expansion for Mounjaro ($10.72 billion, up 65%) and Zepbound ($5.35 billion, up 49%). Incretin medicines represented roughly two-thirds of total revenue for the first nine months of 2026. Consolidated net income for the quarter rose 16% to $6.45 billion ($7.22 diluted EPS), despite absorbing $4.18 billion in acquired in-process research and development (IPR&D) charges from external business development transactions including AtaiBeckley and Curevo. Operating cash flow expanded to $27.42 billion for the first nine months, allowing Lilly to fund aggressive manufacturing expansions ($8.44 billion in CapEx), strategic acquisitions ($10.69 billion net cash paid for acquisitions), and shareholder returns ($4.64 billion in dividends and $4.33 billion in share repurchases). While lower realized prices in the U.S. and China created pricing headwinds, Lilly's manufacturing efficiencies supported an 83.9% gross margin. Management continues to monitor pricing pressures from the Inflation Reduction Act, international reference pricing, and ongoing litigation regarding incretin compounding and patent enforcement.
- Q3 2026 revenue increased 39% year-over-year to $24.40 billion, with Mounjaro generating $10.72 billion and Zepbound generating $5.35 billion.
- Quarterly net income reached $6.45 billion ($7.22 diluted EPS), absorbing $4.18 billion in acquired in-process R&D charges primarily from asset acquisitions of AtaiBeckley and Curevo.
- For the first nine months of 2026, operating cash flow stood at $27.42 billion, funding $8.44 billion in capital expenditures, $18.2 billion in business development activity, and $4.33 billion in share buybacks.
- ·CNBC InvestingFinancials
West Pharma earnings prove it's not just a GLP-1 play
West Pharmaceutical Services reported strong Q3 2026 earnings, with adjusted EPS up 35.7% to $2.66 on sales of $874.5 million, beating analyst expectations. The company raised its full-year adjusted EPS guidance to $9.38-$9.48, citing robust demand for its premium drug-delivery components. While the GLP-1 boom, highlighted by Eli Lilly's 39% revenue growth, is a tailwind, West's growth is also driven by high-value component sales and margin expansion. Proprietary product sales grew 12.6%, with high-value components up 20.3% and now representing 53% of sales. Management expects operating margins to expand by nearly 300 basis points this year, supported by disciplined capital spending. The stock hit a 52-week high of $438.27, reflecting investor confidence in the company's diversified growth strategy.
- West Pharmaceutical Services reported Q3 2026 adjusted EPS of $2.66, up 35.7% year-over-year.
- Q3 sales rose 8.7% to $874.5 million.
- Full-year adjusted EPS guidance raised to $9.38-$9.48 from previous $8.85-$9.05.
- ·AdweekBrand Marketing / Advertising Campaign
Eli Lilly Debuts GLP-1 Ad Targeting Medicare Enrollees
Eli Lilly and Wieden+Kennedy Portland premiered a film called “A Life Covered” to raise awareness among Medicare Part D enrollees about newly available coverage for certain GLP-1 weight-management medications under a CMS demonstration called the Medicare GLP-1 Bridge. The ad — credited to directors Kwedar and Bentley, shot by Linus Sandgren and scored by Caroline Shaw — aims to inform seniors about access and cost (noted as $50/month under the demonstration). Lilly positioned the spot as a consumer awareness effort for patients and seniors; the campaign continues a multi-year partnership between Lilly and Wieden+Kennedy.
- Eli Lilly and Wieden+Kennedy Portland debuted a film titled “A Life Covered.”
- As of July 1, eligible Medicare Part D enrollees can receive certain GLP-1 medications for weight management at $50/month under a CMS demonstration called the Medicare GLP-1 Bridge.
- Lilly products Zepbound KwikPen and orforglipron (sold as Foundayo) are listed as covered under the demonstration and available to Medicare enrollees.
Walgreens
Recent Signals
- ·The DrumRetail Media
Retail media networks shift focus back to onsite ads
A new survey of 61 US retail media network (RMN) leaders by eMarketer and Bain & Company reveals a strategic retreat from offsite formats like social, CTV, and influencers back to onsite product advertising. The survey, conducted in July, found that the top three growth formats for the next year are all onsite: search and sponsored product ads (43%), native AI ads (39%), and display/banner ads (36%). This shift is driven by higher profit margins (70-80% onsite vs. 40% offsite), greater control, and fewer third parties involved. Offsite expansion, including social and in-store, has proven difficult to sell, with social retail media spending under 2% of total US retail media spend. However, the strategy carries risks, as AI assistants could bypass retailer-owned purchase journeys, threatening the sponsored listings that dominate onsite revenue. Only a few well-resourced networks like Best Buy are pursuing big offsite bets.
- Survey of 61 US retail media network leaders conducted in July shows top growth formats for next year are all onsite.
- Onsite advertising generates profit margins of around 70-80% for US retailers, compared to roughly 40% for offsite.
- Retail media spending on social will be about $1.3bn in the US this year, under 2% of total retail media spend.
- ·Modern RetailRetail Media
Walgreens Partners with Looma for In-Store Digital Screens
Walgreens announced a partnership with in-store media firm Looma to deploy digital screens in 1,200 stores starting October, aiming to strengthen its retail media business. The screens, placed near products, will feature advertising and educational content. This initiative follows a previous failed attempt with Cooler Screens, which involved a $200 million dispute. Walgreens emphasizes higher-performing placements and full-funnel metrics. The partnership extends Looma's network, which already includes retailers like Kroger and H-E-B. Industry experts note the potential of pharmacy areas for high dwell-time advertising. Competitor CVS has also been expanding its digital screen presence.
- Walgreens will add digital screens in 1,200 stores starting October.
- Partnership with Looma, which has over 7,000 screens across 10 banners.
- Previous Cooler Screens partnership ended in a $200 million dispute.
- ·The DrumRetail / Physical Stores
Store Closures Can Strengthen Brands, Not Just Signal Retreat
Major retailers including Petsense, Walgreens and others announced store closures in early 2026, with more than 3,300 US stores closed or earmarked for closure in H1 2026. Experts quoted in the article argue that closures can reflect business optimisation rather than systemic decline: cutting unprofitable locations while investing in stronger sites can improve brand health and visibility. The piece contrasts examples such as Tractor Supply closing many Petsense locations while opening namesake stores, Starbucks closing weaker sites but renovating and opening others, and Wayfair expanding into physical stores after heavy digital marketing spend. The analysis concludes that context matters: closures driven by restructuring can be sensible pruning, whereas closures driven by debt and collapsing demand indicate deeper business problems.
- More than 3,300 US stores closed or were earmarked for closure in the first half of 2026.
- The 3,300 figure was 44% lower than the same period in the previous year.
- Tractor Supply decided to close 75 Petsense stores, described as more than a third of Petsense locations, citing negative four-wall cash flow.
Compare their exact ecosystem overlaps.
Explore all deep relationships in Polaris7. Discover exactly which mutual clients, integrated technologies, and overlapping partners Lilly and Walgreens share across the market ecosystem.
Unlock full capability matrix, client overlaps & technology stacks